Dr Cary Adams announces the ATOM Coalition will be structured as an informal alliance comprised of all ATOM partners and key representatives from target countries and led by a governing council. UICC will serve as the Secretariat of the ATOM Coalition and coordinate ATOM partners in their shared ambition to work collectively in target ATOM countries.

He concludes by discussing the next steps. In the first phase of operations, the ATOM Coalition will support the implementation of intensive coordinated capacity building activities in up to 10 countries, expanding to other LLMICs over time, and will focus on increasing access to medicines in over half of countries currently classified as LLMICs.

ATOM Coalition partners
African Organisation for Research and Training in Cancer (AORTIC), American Society for Clinical Oncology (ASCO), American Society for Clinical Pathology (ASCP), AstraZeneca, BeiGene, BIO Ventures for Global Health (BGVH), Bristol Myers Squibb (BMS), Direct Relief, Health Financing Institute, Gilead Sciences, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), International Generic and Biosimilar medicines Association (IGBA), McCabe Centre for Law & Cancer, National Comprehensive Cancer Network (NCCN), Novartis, Project ECHO (Extension for Community Healthcare Outcomes), Roche, Sanofi, Sylvester Comprehensive Cancer Center Global Oncology, Teva, The Defeat-NCD Partnership, The Max Foundation (Max) and the Union for International Cancer Control (UICC)

Watch the interview here